BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26459721)

  • 1. Everolimus in de novo liver transplant recipients: a systematic review.
    Tang CY; Shen A; Wei XF; Li QD; Liu R; Deng HJ; Wu YZ; Wu ZJ
    Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):461-9. PubMed ID: 26459721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis.
    Guan TW; Lin YJ; Ou MY; Chen KB
    Eur J Clin Invest; 2019 Dec; 49(12):e13179. PubMed ID: 31610022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
    Trials; 2015 Mar; 16():118. PubMed ID: 25873064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
    Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bzeizi KI; Smith R; Albenmousa A; Dama M; Aba-Alkhail F; Jalan R; Broering D
    Transplant Proc; 2021; 53(1):148-158. PubMed ID: 33390288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [No Abstract]   [Full Text] [Related]  

  • 7. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
    Su L; Tam N; Deng R; Chen P; Li H; Wu L
    Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
    Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.
    Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Neuhaus P; Gotthardt D; Loss M; Ladenburger S; Paulus EM; Mertens M; Schlitt HJ
    Am J Transplant; 2014 Mar; 14(3):701-10. PubMed ID: 24502384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
    Cillo U; Saracino L; Vitale A; Bertacco A; Salizzoni M; Lupo F; Colledan M; Corno V; Rossi G; Reggiani P; Baccarani U; Bresàdola V; De Carlis L; Mangoni I; Ramirez Morales R; Agnes S; Nure E
    Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.
    De Simone P; Nevens F; De Carlis L; Metselaar HJ; Beckebaum S; Saliba F; Jonas S; Sudan D; Fung J; Fischer L; Duvoux C; Chavin KD; Koneru B; Huang MA; Chapman WC; Foltys D; Witte S; Jiang H; Hexham JM; Junge G;
    Am J Transplant; 2012 Nov; 12(11):3008-20. PubMed ID: 22882750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
    Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
    Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
    Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
    Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.